A Novel Nanobody-Based Immunocytokine of a Mutant Interleukin-2 As a Potential Cancer Therapeutic Publisher

Summary: Can IL-2 fight cancer better? Study finds VGRmIL2-IC targets tumors, boosting efficacy without toxicity. #CancerImmunotherapy #Nanobody

Beig Parikhani A¹ ; Dehghan R¹ ; Talebkhan Y² ; Bayat E² ; Biglari A³ ; Shokrgozar MA⁴ ; Ahangari Cohan R⁵ ; Mirabzadeh E⁶ ; Ajdary S⁷ ; Behdani M¹
Source: AMB Express Published:2024

Abstract

The immunotherapeutic application of interleukin-2 (IL-2) in cancer treatment is limited by its off-target effects on different cell populations and insufficient activation of anti-tumor effector cells at the site of the tumor upon tolerated doses. Targeting IL-2 to the tumor microenvironment by generating antibody-cytokine fusion proteins (immunocytokine) would be a promising approach to increase efficacy without associated toxicity. In this study, a novel nanobody-based immunocytokine is developed by the fusion of a mutant (m) IL-2 with a decreased affinity toward CD25 to an anti-vascular endothelial growth factor receptor-2 (VEGFR2) specific nanobody, denoted as VGRmIL2-IC. The antigen binding, cell proliferation, IFN-γ-secretion, and cytotoxicity of this new immunocytokine are evaluated and compared to mIL-2 alone. Furthermore, the pharmacokinetic properties are analyzed. Flow cytometry analysis shows that the VGRmIL2-IC molecule can selectively target VEGFR2-positive cells. The results reveal that the immunocytokine is comparable to mIL-2 alone in the stimulation of Primary Peripheral Blood Mononuclear Cells (PBMCs) and cytotoxicity in in vitro conditions. In vivo studies demonstrate improved pharmacokinetic properties of VGRmIL2-IC in comparison to the wild or mutant IL-2 proteins. The results presented here suggest VGRmIL2-IC could be considered a candidate for the treatment of VEGFR2-positive tumors. © The Author(s) 2024.